[
  {
    "Drug_ID": "REM45678",
    "NDC_Code": "57894-0030-01",
    "Drug_Name": "Remicade",
    "Generic_Name": "infliximab",
    "GPI_Code": "52.50.30.30.10",
    "Drug_Class": "Tumor Necrosis Factor (TNF) Blocker",
    "Tier_Level": 5,
    "Form": "Powder for Injection",
    "Strength": "100 mg",
    "Route": "Intravenous",
    "Prior_Authorization_Required": true,
    "Step_Therapy_Required": true,
    "Quantity_Limits": "5 vials per infusion, based on weight",
    "Age_Restrictions": "6 years and older",
    "Gender_Restrictions": null,
    "Specialty_Drug": true,
    "Limited_Distribution": false,
    "Plan_ID": "acme Comprehensive Specialty Plus",
    "Copay_Amount": null,
    "Coinsurance_Percentage": 20,
    "Deductible_Applies": true,
    "Maximum_Days_Supply": 56,
    "Network_Restrictions": "Preferred Infusion Centers Only",
    "Effective_Date": "2025-01-01",
    "End_Date": null,
    "Required_Prior_Drugs": [
      {
        "Drug_Name": "Humira",
        "Generic_Name": "adalimumab",
        "For_Indications": [
          "Crohn's Disease",
          "Ulcerative Colitis",
          "Rheumatoid Arthritis"
        ],
        "Minimum_Trial_Period": "12 weeks"
      },
      {
        "Drug_Name": "Mesalamine",
        "Generic_Name": "mesalamine",
        "For_Indications": [
          "Crohn's Disease",
          "Ulcerative Colitis"
        ],
        "Minimum_Trial_Period": "8 weeks"
      }
    ],
    "Failure_Criteria": "Inadequate response, intolerance, or contraindication to required prior therapies",
    "Exception_Criteria": "Documented severe disease requiring immediate biologic therapy; documented adverse reaction to step therapy medications",
    "PA_Criteria": [
      "Diagnosis confirmed by endoscopy or imaging",
      "Moderate to severe disease documented by disease activity scores",
      "Prescribed by or in consultation with a gastroenterologist or rheumatologist",
      "Negative TB test within past 12 months",
      "Negative hepatitis B screening"
    ],
    "Diagnosis_Restrictions": [
      {
        "ICD10_Code": "K50.00",
        "Description": "Crohn's disease of small intestine without complications"
      },
      {
        "ICD10_Code": "K51.90",
        "Description": "Ulcerative colitis, unspecified, without complications"
      },
      {
        "ICD10_Code": "M05.9",
        "Description": "Rheumatoid arthritis with rheumatoid factor, unspecified"
      }
    ],
    "Documentation_Required": [
      "Chart notes documenting diagnosis",
      "Previous treatment history",
      "TB test results",
      "Hepatitis B screening results",
      "Current weight for dose calculation"
    ],
    "Approval_Duration": "Initial: 6 months, Renewal: 12 months",
    "Renewal_Criteria": "Documentation of positive clinical response to therapy"
  },
  {
    "Drug_ID": "HUM28756",
    "NDC_Code": "0074-0243-02",
    "Drug_Name": "Humira",
    "Generic_Name": "adalimumab",
    "GPI_Code": "66.40.10.10.30",
    "Drug_Class": "Tumor Necrosis Factor (TNF) Blocker",
    "Tier_Level": 4,
    "Form": "Solution for Injection",
    "Strength": "40 mg/0.8 mL",
    "Route": "Subcutaneous",
    "Prior_Authorization_Required": true,
    "Step_Therapy_Required": false,
    "Quantity_Limits": "2 pens/syringes per 28 days",
    "Age_Restrictions": "2 years and older (varies by indication)",
    "Gender_Restrictions": null,
    "Specialty_Drug": true,
    "Limited_Distribution": false,
    "Plan_ID": "acme Comprehensive Specialty Plus",
    "Copay_Amount": null,
    "Coinsurance_Percentage": 20,
    "Deductible_Applies": true,
    "Maximum_Days_Supply": 28,
    "Network_Restrictions": "acme Specialty Pharmacy Network",
    "Effective_Date": "2025-01-01",
    "End_Date": null,
    "Required_Prior_Drugs": [
      {
        "Drug_Name": "Methotrexate",
        "Generic_Name": "methotrexate",
        "For_Indications": [
          "Rheumatoid Arthritis",
          "Psoriatic Arthritis",
          "Juvenile Idiopathic Arthritis"
        ],
        "Minimum_Trial_Period": "12 weeks"
      },
      {
        "Drug_Name": "Conventional DMARDs",
        "Generic_Name": "varies",
        "For_Indications": [
          "Rheumatoid Arthritis"
        ],
        "Minimum_Trial_Period": "12 weeks"
      }
    ],
    "Failure_Criteria": "Inadequate response, intolerance, or contraindication to required prior therapies",
    "Exception_Criteria": "Documented severe disease requiring immediate biologic therapy; documented adverse reaction to step therapy medications",
    "PA_Criteria": [
      "Diagnosis confirmed by appropriate clinical evaluation",
      "Moderate to severe disease documented by disease activity scores",
      "Prescribed by or in consultation with a rheumatologist, gastroenterologist, or dermatologist (depending on indication)",
      "Negative TB test within past 12 months",
      "Negative hepatitis B screening"
    ],
    "Diagnosis_Restrictions": [
      {
        "ICD10_Code": "M05.9",
        "Description": "Rheumatoid arthritis with rheumatoid factor, unspecified"
      },
      {
        "ICD10_Code": "K50.90",
        "Description": "Crohn's disease, unspecified, without complications"
      },
      {
        "ICD10_Code": "L40.50",
        "Description": "Arthropathic psoriasis, unspecified"
      },
      {
        "ICD10_Code": "M08.00",
        "Description": "Unspecified juvenile rheumatoid arthritis of unspecified site"
      }
    ],
    "Documentation_Required": [
      "Chart notes documenting diagnosis",
      "Previous treatment history",
      "TB test results",
      "Hepatitis B screening results",
      "Clinical assessment scores if applicable"
    ],
    "Approval_Duration": "Initial: 6 months, Renewal: 12 months",
    "Renewal_Criteria": "Documentation of positive clinical response to therapy"
  },
  {
    "Drug_ID": "ENT96325",
    "NDC_Code": "58468-0132-08",
    "Drug_Name": "Entyvio",
    "Generic_Name": "vedolizumab",
    "GPI_Code": "52.92.00.40.30",
    "Drug_Class": "Integrin Receptor Antagonist",
    "Tier_Level": 5,
    "Form": "Lyophilized Powder for Injection",
    "Strength": "300 mg",
    "Route": "Intravenous",
    "Prior_Authorization_Required": true,
    "Step_Therapy_Required": true,
    "Quantity_Limits": "300 mg per infusion",
    "Age_Restrictions": "18 years and older",
    "Gender_Restrictions": null,
    "Specialty_Drug": true,
    "Limited_Distribution": false,
    "Plan_ID": "acme Comprehensive Specialty Plus",
    "Copay_Amount": null,
    "Coinsurance_Percentage": 20,
    "Deductible_Applies": true,
    "Maximum_Days_Supply": 56,
    "Network_Restrictions": "Preferred Infusion Centers Only",
    "Effective_Date": "2025-01-01",
    "End_Date": null,
    "Required_Prior_Drugs": [
      {
        "Drug_Name": "Humira",
        "Generic_Name": "adalimumab",
        "For_Indications": [
          "Ulcerative Colitis",
          "Crohn's Disease"
        ],
        "Minimum_Trial_Period": "12 weeks"
      },
      {
        "Drug_Name": "Remicade",
        "Generic_Name": "infliximab",
        "For_Indications": [
          "Ulcerative Colitis",
          "Crohn's Disease"
        ],
        "Minimum_Trial_Period": "14 weeks"
      },
      {
        "Drug_Name": "Conventional Therapy",
        "Generic_Name": "varies",
        "For_Indications": [
          "Ulcerative Colitis",
          "Crohn's Disease"
        ],
        "Minimum_Trial_Period": "12 weeks"
      }
    ],
    "Failure_Criteria": "Inadequate response, loss of response, or intolerance to at least one TNF blocker",
    "Exception_Criteria": "Documented contraindication to TNF blockers; history of demyelinating disease or congestive heart failure",
    "PA_Criteria": [
      "Diagnosis of moderate to severe ulcerative colitis or Crohn's disease",
      "Previous failure of or contraindication to conventional therapy",
      "Previous failure of or contraindication to at least one TNF blocker",
      "Prescribed by or in consultation with a gastroenterologist",
      "Negative TB test within past 12 months"
    ],
    "Diagnosis_Restrictions": [
      {
        "ICD10_Code": "K51.90",
        "Description": "Ulcerative colitis, unspecified, without complications"
      },
      {
        "ICD10_Code": "K50.90",
        "Description": "Crohn's disease, unspecified, without complications"
      }
    ],
    "Documentation_Required": [
      "Chart notes documenting diagnosis",
      "Previous treatment history including TNF blockers",
      "TB test results",
      "Disease activity scores or endoscopy results"
    ],
    "Approval_Duration": "Initial: 6 months, Renewal: 12 months",
    "Renewal_Criteria": "Documentation of clinical remission or improvement in signs and symptoms of disease"
  },
  {
    "Drug_ID": "KEY78214",
    "NDC_Code": "00085-1291-01",
    "Drug_Name": "Keytruda",
    "Generic_Name": "pembrolizumab",
    "GPI_Code": "21.10.00.60.30",
    "Drug_Class": "Programmed Death Receptor-1 (PD-1) Blocking Antibody",
    "Tier_Level": 5,
    "Form": "Solution for Injection",
    "Strength": "100 mg/4 mL",
    "Route": "Intravenous",
    "Prior_Authorization_Required": true,
    "Step_Therapy_Required": false,
    "Quantity_Limits": "Based on weight, typically 200mg every 3 weeks",
    "Age_Restrictions": "Varies by indication, generally 18 years and older",
    "Gender_Restrictions": null,
    "Specialty_Drug": true,
    "Limited_Distribution": false,
    "Plan_ID": "acme Comprehensive Specialty Plus",
    "Copay_Amount": null,
    "Coinsurance_Percentage": 20,
    "Deductible_Applies": true,
    "Maximum_Days_Supply": 21,
    "Network_Restrictions": "Preferred Infusion Centers Only",
    "Effective_Date": "2025-01-01",
    "End_Date": null,
    "Required_Prior_Drugs": [],
    "Failure_Criteria": "Not applicable as first-line therapy for many indications",
    "Exception_Criteria": "Not applicable",
    "PA_Criteria": [
      "FDA-approved diagnosis or NCCN-supported indication",
      "Prescribed by or in consultation with an oncologist",
      "Documentation of PD-L1 expression status when required by indication",
      "Documentation of BRAF/MSI/dMMR/TMB-H status when required by indication",
      "ECOG performance status 0-2"
    ],
    "Diagnosis_Restrictions": [
      {
        "ICD10_Code": "C34.90",
        "Description": "Malignant neoplasm of unspecified part of unspecified bronchus or lung"
      },
      {
        "ICD10_Code": "C43.9",
        "Description": "Malignant melanoma of skin, unspecified"
      },
      {
        "ICD10_Code": "C64.9",
        "Description": "Malignant neoplasm of unspecified kidney, except renal pelvis"
      },
      {
        "ICD10_Code": "C20",
        "Description": "Malignant neoplasm of rectum"
      }
    ],
    "Documentation_Required": [
      "Pathology report confirming diagnosis",
      "Genetic/biomarker testing results if applicable (PD-L1, MSI, dMMR, etc.)",
      "Current ECOG performance status",
      "Previous cancer treatments and responses",
      "Recent imaging reports"
    ],
    "Approval_Duration": "Initial: 6 months, Renewal: 12 months",
    "Renewal_Criteria": "No evidence of disease progression and no unacceptable toxicity"
  },
  {
    "Drug_ID": "STE42390",
    "NDC_Code": "69639-0102-01",
    "Drug_Name": "Stelara",
    "Generic_Name": "ustekinumab",
    "GPI_Code": "66.40.10.50.60",
    "Drug_Class": "Interleukin-12 and -23 Inhibitor",
    "Tier_Level": 5,
    "Form": "Solution for Injection",
    "Strength": "90 mg/mL",
    "Route": "Subcutaneous/Intravenous (depending on indication)",
    "Prior_Authorization_Required": true,
    "Step_Therapy_Required": true,
    "Quantity_Limits": "Induction: Single IV dose based on weight; Maintenance: 90 mg subQ every 8 weeks",
    "Age_Restrictions": "6 years and older for psoriasis; 18 years and older for other indications",
    "Gender_Restrictions": null,
    "Specialty_Drug": true,
    "Limited_Distribution": false,
    "Plan_ID": "acme Comprehensive Specialty Plus",
    "Copay_Amount": null,
    "Coinsurance_Percentage": 20,
    "Deductible_Applies": true,
    "Maximum_Days_Supply": 56,
    "Network_Restrictions": "acme Specialty Pharmacy Network",
    "Effective_Date": "2025-01-01",
    "End_Date": null,
    "Required_Prior_Drugs": [
      {
        "Drug_Name": "Humira",
        "Generic_Name": "adalimumab",
        "For_Indications": [
          "Psoriasis",
          "Psoriatic Arthritis",
          "Crohn's Disease",
          "Ulcerative Colitis"
        ],
        "Minimum_Trial_Period": "12 weeks"
      },
      {
        "Drug_Name": "Phototherapy",
        "Generic_Name": "ultraviolet light therapy",
        "For_Indications": [
          "Psoriasis"
        ],
        "Minimum_Trial_Period": "12 weeks"
      },
      {
        "Drug_Name": "Methotrexate",
        "Generic_Name": "methotrexate",
        "For_Indications": [
          "Psoriatic Arthritis"
        ],
        "Minimum_Trial_Period": "12 weeks"
      }
    ],
    "Failure_Criteria": "Inadequate response, intolerance, or contraindication to required prior therapies",
    "Exception_Criteria": "Documented severe disease requiring immediate biologic therapy; documented adverse reaction to TNF blockers",
    "PA_Criteria": [
      "Diagnosis confirmed by appropriate clinical evaluation",
      "Moderate to severe disease documented by disease activity scores",
      "Previous failure of conventional therapy and/or TNF inhibitor",
      "Prescribed by or in consultation with a dermatologist, rheumatologist, or gastroenterologist",
      "Negative TB test within past 12 months"
    ],
    "Diagnosis_Restrictions": [
      {
        "ICD10_Code": "L40.0",
        "Description": "Psoriasis vulgaris"
      },
      {
        "ICD10_Code": "L40.50",
        "Description": "Arthropathic psoriasis, unspecified"
      },
      {
        "ICD10_Code": "K50.90",
        "Description": "Crohn's disease, unspecified, without complications"
      },
      {
        "ICD10_Code": "K51.90",
        "Description": "Ulcerative colitis, unspecified, without complications"
      }
    ],
    "Documentation_Required": [
      "Chart notes documenting diagnosis",
      "Previous treatment history",
      "TB test results",
      "Clinical assessment scores (PASI, BSA for psoriasis; CDAI for Crohn's; Mayo for UC)",
      "Current weight for dose calculation (for Crohn's/UC IV induction)"
    ],
    "Approval_Duration": "Initial: 6 months, Renewal: 12 months",
    "Renewal_Criteria": "Documentation of positive clinical response to therapy"
  },
  {
    "Drug_ID": "OCR12549",
    "NDC_Code": "50242-0150-01",
    "Drug_Name": "Ocrevus",
    "Generic_Name": "ocrelizumab",
    "GPI_Code": "62.20.22.30.40",
    "Drug_Class": "CD20-Directed Cytolytic Antibody",
    "Tier_Level": 5,
    "Form": "Solution for Injection",
    "Strength": "300 mg/10 mL",
    "Route": "Intravenous",
    "Prior_Authorization_Required": true,
    "Step_Therapy_Required": true,
    "Quantity_Limits": "Initial: 300 mg on day 1 and 15; Maintenance: 600 mg every 6 months",
    "Age_Restrictions": "18 years and older",
    "Gender_Restrictions": null,
    "Specialty_Drug": true,
    "Limited_Distribution": false,
    "Plan_ID": "acme Comprehensive Specialty Plus",
    "Copay_Amount": null,
    "Coinsurance_Percentage": 20,
    "Deductible_Applies": true,
    "Maximum_Days_Supply": 180,
    "Network_Restrictions": "Preferred Infusion Centers Only",
    "Effective_Date": "2025-01-01",
    "End_Date": null,
    "Required_Prior_Drugs": [
      {
        "Drug_Name": "Interferon beta-1a",
        "Generic_Name": "interferon beta-1a",
        "For_Indications": [
          "Relapsing Multiple Sclerosis"
        ],
        "Minimum_Trial_Period": "12 weeks"
      },
      {
        "Drug_Name": "Glatiramer Acetate",
        "Generic_Name": "glatiramer acetate",
        "For_Indications": [
          "Relapsing Multiple Sclerosis"
        ],
        "Minimum_Trial_Period": "12 weeks"
      },
      {
        "Drug_Name": "Dimethyl Fumarate",
        "Generic_Name": "dimethyl fumarate",
        "For_Indications": [
          "Relapsing Multiple Sclerosis"
        ],
        "Minimum_Trial_Period": "12 weeks"
      }
    ],
    "Failure_Criteria": "Inadequate response, intolerance, or contraindication to at least two MS disease-modifying therapies",
    "Exception_Criteria": "Primary progressive MS diagnosis (no step therapy required); highly active relapsing MS with rapid progression",
    "PA_Criteria": [
      "Diagnosis of relapsing or primary progressive multiple sclerosis confirmed by MRI",
      "For relapsing MS: prior failure of at least two disease-modifying therapies, unless exception criteria are met",
      "Prescribed by or in consultation with a neurologist",
      "No active hepatitis B infection",
      "No active malignancy"
    ],
    "Diagnosis_Restrictions": [
      {
        "ICD10_Code": "G35",
        "Description": "Multiple sclerosis"
      }
    ],
    "Documentation_Required": [
      "MRI reports confirming diagnosis",
      "Neurologist consultation notes",
      "Previous MS treatment history and response",
      "Hepatitis B screening results",
      "JC virus antibody status (if previously on natalizumab)"
    ],
    "Approval_Duration": "Initial: 6 months, Renewal: 12 months",
    "Renewal_Criteria": "Documentation of stable or improved disease activity; no significant adverse events"
  }
]
